Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study
- PMID: 1709154
- DOI: 10.1007/BF00194556
Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study
Abstract
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
Similar articles
-
Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.Invest New Drugs. 1991 Feb;9(1):53-7. doi: 10.1007/BF00194545. Invest New Drugs. 1991. PMID: 1709152 Clinical Trial.
-
Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study.Am J Clin Oncol. 1993 Aug;16(4):327-8. doi: 10.1097/00000421-199308000-00010. Am J Clin Oncol. 1993. PMID: 8328410 Clinical Trial.
-
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.Invest New Drugs. 1990 Feb;8(1):77-80. doi: 10.1007/BF00216928. Invest New Drugs. 1990. PMID: 2188928 Clinical Trial.
-
A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.Invest New Drugs. 1993 Nov;11(4):329-31. doi: 10.1007/BF00874432. Invest New Drugs. 1993. PMID: 8157474 Clinical Trial.
-
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.Invest New Drugs. 2004 Aug;22(3):335-41. doi: 10.1023/B:DRUG.0000026261.76197.54. Invest New Drugs. 2004. PMID: 15122082 Clinical Trial.
Cited by
-
New insight into the molecular mechanisms of the biological effects of DNA minor groove binders.PLoS One. 2011;6(10):e25822. doi: 10.1371/journal.pone.0025822. Epub 2011 Oct 5. PLoS One. 2011. PMID: 21998702 Free PMC article.
-
Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA.Org Lett. 2010 Aug 6;12(15):3300-3. doi: 10.1021/ol100923d. Org Lett. 2010. PMID: 20597468 Free PMC article.
-
Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.FEBS Lett. 2015 Jun 4;589(13):1498-504. doi: 10.1016/j.febslet.2015.04.044. Epub 2015 May 1. FEBS Lett. 2015. PMID: 25937122 Free PMC article.
-
Imidazoles as potential anticancer agents.Medchemcomm. 2017 Apr 13;8(9):1742-1773. doi: 10.1039/c7md00067g. eCollection 2017 Sep 1. Medchemcomm. 2017. PMID: 30108886 Free PMC article. Review.
-
KCa3.1-dependent uptake of the cytotoxic DNA-binding dye Hoechst 33258 into cancerous but not healthy cervical cells.J Biol Chem. 2021 Jan-Jun;296:100084. doi: 10.1074/jbc.RA120.013997. Epub 2020 Nov 23. J Biol Chem. 2021. PMID: 33199365 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical